Horizon Pharma has announced positive Phase III clinical trial data for teprotumumab, as a treatment for active thyroid eye disease (TED).Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.